Enveric Biosciences, Inc. ENVB NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score

37/100

1/5 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

Income Statement Balance Sheet Cash Flow Statement

Annual Quarterly

Enveric Biosciences, Inc. (ENVB) reported total assets of $5.1M and total liabilities of $918.4K for fiscal year 2025, resulting in total equity of $4.18M.

The company held $4.68M in cash and short-term investments. Total debt stood at $0.00, with net debt of $-4.68M. The Debt-to-Equity (D/E) ratio was 0 (conservative).

Current ratio is 5.38, indicating strong short-term liquidity. Interest coverage is -82777.8x (weak).

Criteria supported by this page:

HEALTH (67/100, Partial) — some metrics are adequate but not all reach ideal thresholds
MOAT (28/100) — Total assets $5.1M and equity $4.18M support the company's competitive scale

Overall SharesGrow Score: 35/100 with 1/7 criteria passed.

SharesGrow 7-Criteria Score

37/100

SG Score

View full scorecard →

—

VALUE

N/A

No coverage

✓

FUTURE

75/100

Analyst consensus

→ Forecast

✗

PAST

0/100

→ Income

HEALTH

67/100

Debt-to-Equity & liquidity

Proven by this page

✗

MOAT

28/100

→ Income

✗

GROWTH

15/100

→ Income

—

INCOME

N/A

No coverage

Enveric Biosciences, Inc. Balance Sheet History

Metric	FY2025	FY2024	FY2023	FY2022
Total Assets	$5.1M	$3.08M	$4.3M	$19.55M
Total Liabilities	$918.4K	$1.49M	$2.34M	$4M
Total Debt	$0.00	$0.00	$0.00	$63.82K
Cash & Investments	$4.68M	$2.24M	$2.29M	$17.72M
Total Stockholders Equity	$4.18M	$1.59M	$1.96M	$14.67M